New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept

New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept

Etanercept is a recombinant fusion protein approved for the treatment of TNF-α mediated diseases such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, and ankylosing spondylitis. Herein, we present an evaluation of the physicochemical and biological properties of a biosimilar etanercept...

Full description

Bibliographic Details
Main Authors:	Mariana P. Miranda-Hernández, Carlos A. López-Morales, Francisco C. Perdomo-Abúndez, Rodolfo D. Salazar-Flores, Nancy D. Ramírez-Ibanez, Nestor O. Pérez, Aarón Molina-Pérez, Jorge Revilla-Beltri, Luis F. Flores-Ortiz, Emilio Medina-Rivero
Format:	Article
Language:	English
Published:	Hindawi Limited 2016-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2016/9697080

Similar Items

Response to: Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
by: Mariana P. Miranda-Hernández, et al.
Published: (2018-01-01)

Pharmacokinetic Comparability of a Biosimilar Trastuzumab Anticipated from Its Physicochemical and Biological Characterization
by: Mariana P. Miranda-Hernández, et al.
Published: (2015-01-01)

Comment on “New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept”
by: Brian Hassett, et al.
Published: (2018-01-01)

Physicochemical and Biological Characterization of a Biosimilar Trastuzumab
by: Carlos A. López-Morales, et al.
Published: (2015-01-01)

Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity
by: Mariana P. Miranda-Hernández, et al.
Published: (2015-01-01)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
by: Anna Felis-Giemza, et al.
Published: (2019-10-01)

Focus on biosimilar etanercept – bioequivalence and interchangeability
by: Cantini F, et al.
Published: (2018-08-01)

Clinical experience with two etanercept biosimilars in Indian patients with spondyloarthritis
by: Ashok Kumar, et al.
Published: (2017-01-01)

Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
by: Hans C. Ebbers, et al.
Published: (2019-08-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Economic impact of biosimilar drugs in Italy: past, present and future of infliximab and etanercept
by: Andrea Marcellusi, et al.
Published: (2017-07-01)

Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
by: V. Shobha, et al.
Published: (2019-07-01)

Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
by: Roberto Ravasio, et al.
Published: (2018-04-01)

Physicochemical and Biological Characterization of the Proposed Biosimilar Tocilizumab
by: Shiwei Miao, et al.
Published: (2017-01-01)

Structural and In Vitro Functional Comparability Analysis of Altebrel™, a Proposed Etanercept Biosimilar: Focus on Primary Sequence and Glycosylation
by: Ramin Fazel, et al.
Published: (2019-01-01)

Characterization and comparability of biosimilars: A filgrastim case of study and regulatory perspectives for Latin America
by: Karina Mendoza-Macedo, et al.
Published: (2016-11-01)

Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
by: Janusz Jaworski, et al.
Published: (2019-05-01)

LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH AUTOIMMUNE DISEASES TREATED WITH INFLIXIMAB AND ETANERCEPT
by: Luis Gabriel Parra-Lara
Published: (2019-04-01)

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
by: Kun-Peng Li, et al.
Published: (2018-06-01)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
by: Stefan Schreiber, et al.
Published: (2020-06-01)

Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01)

Etanercept (review of international studies)
by: D E Karateev
Published: (2009-10-01)

Use of anti-TNF Etanercept in paediatric patients with autoimmune disease and ocular involvement: the Parma experience
by: Rossi M, et al.
Published: (2008-09-01)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
by: Joon-Cheol Kwon, et al.
Published: (2021-06-01)

Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
by: Parag Goyal, et al.
Published: (2021-01-01)

Biosimilars
Published: (2022)

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study
by: Min-Chan Park, et al.
Published: (2019-05-01)

Etanercept: Indian perspective
by: Murlidhar Rajagopalan, et al.
Published: (2015-01-01)

ETANERCEPT WITHDRAWAL IN JIA
by: Oana-Maria Farkas, et al.
Published: (2017-06-01)

Disease activity guided stepwise tapering or discontinuation of rhTNFR:Fc, an etanercept biosimilar, in patients with ankylosing spondylitis: a prospective, randomized, open-label, multicentric study
by: Ting Zhang, et al.
Published: (2020-05-01)

Estudos de medicamentos biosimilares Studies on biosimilar medications
by: Winston Bonetti Yoshida
Published: (2010-09-01)

Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
by: An Q, et al.
Published: (2019-03-01)

Pharmacoeconomic aspects of biosimilars
by: A A Tryakin, et al.
Published: (2017-01-01)

Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature
by: Madenidou Anastasia-Vasiliki, et al.
Published: (2019-01-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Biosimilars in Europe
Published: (2023)

Psoriasis, lymphoma and etanercept: is there a correlation? Psoríase, linfoma e etanercepte: existe correlação?
by: Ludmilla Queirós Miranda, et al.
Published: (2012-02-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)

Myoclonus in patients treated with etanercept
by: V. Domínguez Leñero, et al.
Published: (2014-01-01)

Etanercept in the treatment of plaque psoriasis
by: Thao U Nguyen, et al.
Published: (2009-05-01)